Lite Strategy (LITS) Other Non-Current Liabilities (2011 - 2026)
Lite Strategy (LITS) posted Other Non-Current Liabilities of $2.0 million for Q1 2026, little changed on a QoQ basis from $2.0 million in Q4 2025, and down 59.18% year-over-year from $4.9 million in Q1 2025.
Analysis
Lite Strategy (LITS) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Lite Strategy has reported Other Non-Current Liabilities for 10 years, with the latest figure at $2.0 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 59.18% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 59.18% decrease from a year earlier, with the FY2022 full-year figure at $1.6 million, down 92.84% from the prior year.
- Other Non-Current Liabilities was $2.0 million for Q1 2026 at Lite Strategy, roughly flat from $2.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $4.9 million in Q3 2023, with the low at $500000.0 in Q3 2022.
- Average Other Non-Current Liabilities over 5 years is $3.3 million, with a median of $3.4 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 97.47% in 2022, then surged 880.0% in 2023.
- Over 5 years, Other Non-Current Liabilities stood at $500000.0 in 2022, then soared by 880.0% to $4.9 million in 2023, then changed by 0.0% to $4.9 million in 2024, then sank by 59.18% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 4.90 Mn |
| Dec 31, 2024 | 4.90 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Dec 31, 2023 | 4.90 Mn |
| Sep 30, 2023 | 4.90 Mn |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.54 Mn |
| Dec 31, 2021 | 14.31 Mn |
| Sep 30, 2021 | 19.80 Mn |
| Jun 30, 2021 | 22.40 Mn |
| Mar 31, 2021 | 29.44 Mn |
| Dec 31, 2020 | 20.18 Mn |
| Sep 30, 2020 | 27.26 Mn |
| Jun 30, 2020 | 40.50 Mn |
| Mar 31, 2020 | 9.05 Mn |